You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Revascularisation led to less angina and fewer adverse cardiac events than did optimal medical care in angina pectoris in the elderly

Article Text

Article menu
Download PDFPDF
Therapeutics
Revascularisation led to less angina and fewer adverse cardiac events than did optimal medical care in angina pectoris in the elderly

https://doi.org/10.1136/ebm.7.2.45

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Lancet 358, 951. The TIME Investigators.. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.. Sep 22;. :. –7.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In older patients with at least Canadian Cardiac Society (CCS) class II angina pectoris, is an invasive strategy of left heart catheterisation followed by either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) more effective than a strategy of optimised medical treatment?

    Design

    Randomised (allocation concealed*), unblinded,* controlled trial with 6 months of follow up.

    Setting

    {14 university and non-university hospitals}† in Switzerland.

    Patients

    305 patients who were ≥ 75 years of age (mean age 80 y, 56% men) with at least CCS class II angina pectoris despite treatment with ≥ 2 antianginal drugs. Exclusion criteria included acute myocardial infarction (MI) within the previous 10 days, concomitant valvular or other heart disease, predominant congestive heart failure, and life-limiting comorbid disease. 4 patients (2 …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by the author.

    • Sources of funding: Swiss Heart Foundation Berne, Switzerland, and ADUMED Foundation, Switzerland.

    • For correspondence: Professor M Pfisterer, University Hospital, Basel, Switzerland. pfisterer{at}email.ch.